{"id":"W2148766438","doi":"10.1016/s0140-6736(12)61769-3","title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1198,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital; McGill University","funders":"National Institute for Health and Care Research","keywords":"Alemtuzumab; Medicine; Interferon beta-1a; Multiple sclerosis; Internal medicine; CD52; Clinical endpoint; Randomized controlled trial; Gastroenterology; Interferon beta; Immunology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1458615041298442,"score_gpt":0.3623954771154779,"score_spread":0.2165339729856337,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}